	US 11,673,956 B2
	Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1
Margaret A. Shipp, Wellesley, MA (US); Jing Ouyang, Sharon, MA (US); and Scott J. Rodig, Westwood, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on Oct. 7, 2020, as Appl. No. 17/65,151.
Application 16/050,513 is a division of application No. 14/907,418, abandoned, previously published as PCT/US2014/047784, filed on Jul. 23, 2014.
Application 17/065,151 is a continuation of application No. 16/050,513, filed on Jul. 31, 2018, granted, now 10,844,126.
Claims priority of provisional application 61/911,031, filed on Dec. 3, 2013.
Claims priority of provisional application 61/857,839, filed on Jul. 24, 2013.
Prior Publication US 2021/0095035 A1, Apr. 1, 2021
Int. Cl. C12N 1/20 (2006.01); C12N 5/02 (2006.01); C12N 15/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); C07K 16/18 (2006.01); G01N 33/577 (2006.01); A61K 39/00 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2851 (2013.01) [A61K 39/0005 (2013.01); C07K 16/18 (2013.01); G01N 33/577 (2013.01); G01N 33/57484 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

4 Claims

1. An expression vector comprising 1) a cDNA having a sequence that encodes residues 102-115 of a polypeptide selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, and 16, wherein the encoded sequence from the polypeptide is only as long as required to encode the residues 102-115 of the polypeptide and 2) a promoter to which the cDNA is operably linked.